Once again, more than three-quarters of U.S. venture capital (VC) dollars went to companies in California, New York and Massachusetts in 2016, according to data from the PricewaterhouseCoopers (PwC)/CB Insights’ Moneytree Report Explorer. Approximately 53.3 percent of all VC capital went to California companies, down nearly 4.4 percent from the states peak in 2014 (57.7) and down 3.9 percent from 2016. While California’s share declined, both Massachusetts and New York saw increases in their share of VC dollars invested:


Patients everywhere take their medication with emocha.

This World TB Day, we want to say thank you to our partners around the world who are uniting to #EndTB.

Patients across three continents are using the emocha platform to facilitate TB treatment, and we’re proud to support hundreds of healthcare workers as they fight to eradicate TB.

Public health departments in California, Maryland, Texas, Missouri, Washington, Rhode Island, and Puerto Rico have adopted emocha’s video DOT platform for active and latent TB monitoring. Sites in Australia, India, and Mexico have also implemented the technology, proving that video DOT is an effective strategy for combating global TB.


Patients could one day self-administer vaccines using a needleless, pill-sized technology that jet-releases a stream of vaccine inside the mouth, according to a proof-of-concept study conducted at UC Berkeley.

The study did not test vaccine delivery in people, but demonstrated that the technology, called MucoJet, is capable of delivering vaccine-sized molecules to immune cells in the mouths of animals. The technology is a step toward improved oral vaccine delivery, which holds the promise of building immunity in the mouth’s buccal region of cells, where many infections enter the body. When patients hold the MucoJet against the inside of their cheek, the device releases a jet stream that directly targets the buccal region. This region is rich in immune cells but underutilized in immunology because of the challenge of efficiently penetrating the thick mucosal layer in this part of the oral cavity with existing technologies, such as the oral spray often used for influenza vaccination.


Get a sneak peak of the Mobile eXploration Lab (MXLab) – the country’s largest, most advanced mobile STEM laboratory! MdBio is launching the MXLab for the 2017/2018 school year, and we want to give teachers across the state the first chance to see the lab in action and provide feedback on our activities for Maryland high schools.

Join us at one of five events across the state to get a sneak peek of the MXLab plus a hands-on teacher professional development activity for your classroom.


On Tuesday, March 7, 2017, the University of Maryland (UMD) Robert E. Fischell Institute for Biomedical Devices and RTI International (link is external) welcomed nearly 150 representatives of Maryland’s medical device ecosystem to a daylong event focused on bringing products from invention to market in the state. The event, Medical Device Innovation in Maryland: from Technology to Lab to Market, took place at the UMD campus in College Park, and culminated with a tour of the soon-to-be new home of the A. James Clark School of Engineering: A. James Clark Hall.

“This is the start of an incredibly exciting time for biomedical devices in Maryland – and you’re here at the beginning,” University of Maryland Provost Mary Ann Rankin told attendees.


Symbiomix today announced that the US Food and Drug Administration (FDA) has accepted for filing the Company’s New Drug Application (NDA) for its lead investigational product candidate Solosec™ (secnidazole oral granules), an innovative antibiotic designed to treat bacterial vaginosis (BV). In accordance with the FDA’s priority 6-month review designation, the agency has established a user-fee goal date under the Prescription Drug User Fee Act (PDUFA) of September 17, 2017. Symbiomix submitted the NDA filing in January 2017.

Solosec™ is a potent, next-generation, investigational 5-nitroimidazole antibiotic with enhanced pharmacokinetic properties, which will be the first and only single-dose oral therapy approved for BV if approved by the FDA. The FDA previously designated Solosec™ as a Qualified Infectious Disease Product (QIDP) for the treatment of BV and granted it Fast Track designation, which made Solosec™ eligible for priority review and at least 10 years of market exclusivity.


What’s next for the pharmaceuticals industry, amid digital disruption and rapid technological advances? McKinsey’s Martin Dewhurst sat down for a wide-ranging conversation with David Epstein of venture firm Flagship Pioneering to explore ways the sector could shift in coming years. In this interview, part of our Biopharma Frontiers series on how the pharmaceutical industry is evolving and how leaders can adapt, Epstein discusses the next horizon of innovation, critical elements of an effective business, and the kind of culture he tries to foster. An edited transcript of their conversation follows.


Dear Friends of CONNECTpreneur:

I hope everything is well! This is a "Last Call" for our April 4 Big Idea CONNECTprenuer SPRING FORUM at the Hyatt Regency in Bethesda, MD. We expect over 500 CXOs, founders, entrepreneurs, angel investors, etc., and we will be completely SOLD OUT again. So, please sign up now!

We have unparralled CXO to CXO networking, plus an amazing program:

Fireside chat with DAVID TRONE, Co-Founder and Owner, Total Wine & More

Awesome Entrepreneur "War Stories" Panel (moderated by GLEN HELLMAN (aka Mr. Cranky), angel investor and CEO of Driven Forward) featuring:
· NIGEL JONES, CEO of Koolspan and Managing Director of TWJ Capital
· BETH MALONEY, President of Palladian Partners
· D.P. VENKATESH, VP of Broadsoft and CEO of mPortal

PLUS 9 awesome early stage companies will present their companies.


Host:  UM BioPark & Wexford + Technology

Location:  UM BioPark Life Sciences Conference Center, 801 W. Baltimore Street, Baltimore, Maryland  21201

Date:  March 30, 2017 - 5:00pm to 6:30pm

Please join the BioPark's Monthly Networking Event along with collegues from the Maryland Proton Treatment Center. Mingle with MPTC leadership and staff, BioPark tenants, and UMB faculty and staff.


The co-founders of a Johns Hopkins-backed startup had personal motivations for developing better health care tracking technology.

The mother of Sathya Elumala, who is CEO of Multisensor Diagnostics, suffers from multiple chronic health conditions and spends time in hospitals almost every month. Gene Fridman, the company's chief technology officer, lost a sister who had a chronic condition that wasn't detected soon enough.


Vaccines may be available for pneumococcal infections, but none of them, including the widely used Prevnar 13, can cover all strains. SutroVax is one of the startups trying to solve that problem, and today raised $64 million to test its approach in humans.

New investors Frazier Healthcare Partners and Pivotal bioVenture Partners led the Series B financing round for Foster City, CA-based SutroVax. Also participating in the round were earlier investors Abingworth, Longitude Capital, Roche Venture Fund, and CTI Life Sciences Fund. In addition to the $60 million Series B investment, SutroVax says the earlier investors are also putting another $4 million into the company.


The National Science Foundation's Small Business Innovation Research (SBIR) program provides small business with equity-free funding to conduct research and development (R&D) work and de-risk technology for commercial success. The NSF SBIR program accepts innovative proposals that show promise of commercial and societal impact in almost all areas of technology.

SBIR Phase I proposals are expected to undertake R&D with the aim of establishing technical feasibility or proof of concept. Successful applicants will receive a grant of up to $225,000 over a period of 6 to 12 months (the period to be decided by the company).

Successful SBIR proposers will receive funding about 6 months after the solicitation deadline. Companies that receive a Phase I award are eligible to apply for a Phase II award (award amount up to $750,000; duration 2 years).


In order for America to maintain its innovative and technological competitive advantage, it is imperative that current policy design favor high growth formation through the catalytic means of institutional financing. The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs have historically served as crucial financing to help de-risk early-stage technology development and enable validation that encourages follow-on private institution capitalization. With new trends in the Internet of Things, artificial intelligence, advanced materials, genomics, environmental sustainability, renewable energy, national security, and many other areas evolving over the years ahead, national governments bear the responsibility for helping seed the inventive fire that enables economic growth as we move forward.



If you do business with the government, you are a target for cyber-attacks!

If you are a government contractor, join us to learn how to implement a strong and cost effective cybersecurity program that will strengthen your company's cybersecurity posture and help you meet requirements necessary to do business with the federal government. As an attendee, you can receive two customized assessments to help identify your company’s level of exposure: (1) a mini cyber-risk review from CyberRx that will assess your company’s cyber capabilities within the Cybersecurity Framework; and (2) a threat intelligence assessment from Wapack Labs that can help to identify if your organization has been or will be the victim of an attack. Space is limited. Register today.


Pulmocide raised $30.4 million in a Series B round of financing to support the early clinical development of its lead inhaled drugs against respiratory syncytial virus (RSV) and pulmonary aspergillosis. The fundraising round was led by new investor SR One and included the Longwood Fund and existing investors SV Life Sciences, F-Prime Capital, Johnson & Johnson Innovation–JJDC, and Touchstone Innovations.


The University of Maryland University College is tearing itself apart -- on purpose.

The university, which gets nearly all of its funding from tuition revenue, has long relied on enrolling large numbers of students associated with the military for financial stability. After teaching students at military bases across Asia and Europe for decades, the university was quick to realize the potential of the internet and became a pioneer in the field of distance education.


Friday, April 14, 2017 7:30 AM - 9:30 AM

Bethesda Marriott - 5151 Pooks Hill Road Bethesda, MD 20814

With the transition to the Trump administration, change is coming rapidly in the form of legislative proposals, regulations (or repeal thereof), and policy statements. How will all this affect the ability of tech companies to raise the capital they need to grow. Amid this shifting ground, we’ve asked an expert panel of our own Maryland technology companies to talk about their recent successes and challenges in raising capital and their outlook for the ability of Maryland technology companies to do the same. Our panel, moderated by David Straut of Wells Fargo, includes two long-time local tech CFOs who have had recent success raising money and the Director of the Maryland Venture Fund, which oversees investments in approximately 50 local technology ventures

Financial Executives Forum: FEF is devoted to peer-to-peer connections and programs that highlight the latest topics of interest for the region’s leading business and financial executives. FEF encourages participants to connect as well as learn from some of the area’s preeminent executives, policymakers and thought leaders.


May 18, 2017 - 8 a.m. - 4 p.m. - Hilton Baltimore

Join Governor Hogan for the first Maryland Governor’s Business Summit. Explore topics on human capital, global trends and business strategy. Connect with a wide array of Maryland’s business leaders.

Maryland map flag

Newsflash: The Association of University Technology Managers met in Hollywood, Fla., and had its own Final Four last week.

All of the finalists of the conference’s pitch competition had a common bond: They each had ties to Maryland universities such as Johns Hopkins and University of Maryland. All four also received funding from TEDCO’s Maryland Innovation Initiative.

BioHealth Innovation (BHI) is pleased to have the opportunity to discuss the entrepreneurial ecosystem in Maryland and the region.

BHI is a regional innovation intermediary which supports the transformation of research projects into new business opportunities in partnership with the region’s rich assets, institutions, and entrepreneurial community. BHI achieves this goal by being a catalytic partner in the economic development ecosystem which focuses on attracting, retaining, founding and reinventing biohealth businesses. BHI has built the infrastructure and track record to cofound and create new early stage biohealth startup and spinoff companies. In addition, BHI works directly with existing biohealth firms through a variety of supportive services including: incubation and accelerator programs, non-dilutive funding assistance, international soft landing programs and entrepreneur-in-residence support.


The University of Maryland, Baltimore (UMB) today announced the appointment of Marco Chacón, PhD, as Assistant Vice President, Industry Alliances. In this role, Dr. Chacón, a seasoned biopharmaceutical executive and entrepreneur, will work with the Office of Research and Development, UM Ventures, and University of Maryland BioPark teams, leading special projects to grow the BioPark tenant base and strengthen the University’s research collaborations with industry.

 “Marco is a distinguished scientist, entrepreneur, and biopharma CEO who has spent many years working as a valued member of the UM BioPark community,” said James L. Hughes, Vice President and Chief Enterprise & Economic Development Officer and president of the corporation that manages the UM BioPark. “His accomplishments leading a successful contract development and manufacturing organization, along with his deep industry and government connections, make him a superb addition to our team at UMB.


Pharmaron, a fully integrated contract research organization offering R&D services to the life sciences industry, today announced that it has signed a definitive agreement under which Pharmaron will acquire a majority stake in Shin Nippon Biomedical Laboratories Clinical Pharmacology Center, Inc. (“SNBL CPC”) in Baltimore, Maryland, USA. This clinical center is a leading provider of moderate and highly complex Phase I/II clinical development services for the life sciences sector. Current shareholder Shin Nippon Biomedical Laboratories, Ltd. (SNBL) (TSE:2395) will retain a minority stake in the business following the transaction.


On an afternoon in early February, Richard May, the head of a new Baltimore nonprofit, stands braced against the wind and sketches out a vision for West Baltimore. It begins here, on a blighted section of North Avenue not far from the Maryland Institute College of Art, where a graveyard of a public housing project, unoccupied for almost two years, is currently being torn down.


Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has signed a two-year contract with the Biomedical Advanced Research and Development Authority (BARDA), a division within the Office of the Assistant Secretary of Preparedness and Response, valued at $100 million for the delivery of BioThrax® (Anthrax Vaccine Adsorbed) to the Strategic National Stockpile (SNS). This contract satisfies BARDA's notice of intent to sole source BioThrax that was issued on December 8, 2016 and is separate from and in addition to the company’s $911 million BioThrax procurement contract with the Centers for Disease Control and Prevention (CDC). BioThrax pricing under this BARDA procurement contract is the same as BioThrax pricing under the CDC follow-on contract.

“Emergent is pleased to support BARDA in its efforts to enhance the nation’s preparedness against the threat of anthrax,” said Adam Havey, executive vice president and president biodefense division at Emergent BioSolutions. “Emergent is committed to developing and manufacturing preparedness solutions that address our customers’ needs to protect against a broad spectrum of public health threats.”


Monday, April 3, 2017 11:00 AM – 6:00 PM EDT

SMC Campus Center 621 West Lombard Street Elm Room A & B Baltimore, MD 21201

The Entrepreneurship and Innovation Network (EIN) is pleased to present the 1st annual Entrepreneurship and Innovation Expo at University of Maryland, Baltimore.

Join us for a half day event celebrating all of the entrepreneurial and innovative endeavors at UMB. Events will include talks entrepreneurs at the student, faculty and student levels as well as a keynote presentation from the UMB Presidents White Paper Fellows. Other events will include tabling sessions from local entrepreneurial entities and groups.


The 2017 Maryland Incubator Company of the Year Awards publicly recognizes achievements by current clients and graduates of Maryland incubators and provides a forum for the nominees to increase their visibility in the business, technology and investment communities.

Business incubators support new and early-stage businesses in Maryland. In 1986, the first public incubator was established at the University of Maryland in College Park. Recognizing the economic challenges facing new companies, business incubators are facilities that provide reasonable market rents, shared services and technical assistance to start-ups and early-stage companies, including manufacturing, biotech, service and technology firms.


A growing tech industry is often considered the ultimate sign of a healthy local economy. By that measure, the Bay Area still stands at the top of the heap in the United States, but our survey of the metropolitan areas with the strongest tech job growth turns up some surprising places not usually thought of as tech meccas.


A pair of medicine and nursing alumni have made a $1.5 million gift to the University of Maryland's Health Science & Human Services Library to establish a health care innovation center.

The center intends to provide an encouraging environment where doctors, medical students, nurses and other practitioners think in new ways about how to improve the doctor-patient relationship as a means of improving health care delivery, according to university officials who announced the funding Thursday.


When Americans think about U.S. leadership in the world, they often think of military power, famous presidents, or economic achievement. But they might be less likely to name an area in which the United States has led the world for decades: science.

From lifesaving vaccines for devastating diseases like smallpox and polio, to novel materials like semiconductors and superconductors, to robotic rovers that can explore Mars, science has made possible discoveries that revolutionized the world, and much of it started right here in the United States.


To increase new company creation and commercialization of its leading-edge research, the University System of Maryland (USM) is launching a $25 million early-stage investment fund to be known as the Maryland Momentum Fund.

The money-raising process for start-up companies typically is an uneven one. Therefore, the Maryland Momentum Fund will concentrate on filling gaps in the funding pipeline to push USM's most innovative ideas into the marketplace.


The Trump Administration’s skinny budget proposal released today calls itself, “A Budget Blueprint to Make America Great Again.” From the information contained in the document, it is clear the Administration does not view science, technology, innovation and entrepreneurship and the economic development efforts built around those activities as the path forward to making “America great again.” The program eliminations and drastic cuts are not the way to move the country forward economically. So what is behind this proposal? Two things: 1) a fight over the proper role of the federal government in the economy, and 2) a negotiating tactic to attempt to lull advocates into thinking program survival or lesser cuts are a victory. A full community response is needed and all of us must get off the sidelines and on to the playing field.


Digital health leader WellDoc® and the Healthy Trucking Association of America (HTAA) announced today their partnership to help truckers living with diabetes. Additionally, WellDoc unveils its consumer diabetes health app, BlueStar® C, which is designed to aid individuals living with diabetes to manage their chronic condition.

Both organizations, through this initial launch, will introduce BlueStar C to truckers and fleets at the Mid-America Trucking Show (MATS) in Louisville, Kentucky, which takes place from March 23-25. Renegade Radio Nashville (RRN) is also partnering with HTAA and WellDoc, as the national media partner for BlueStar C. RRN’s President and COO Jack Aponte (also known as on-air personality “Captain Jack”) will join the HTAA and WellDoc teams at the MATS Booth (#76 173) to help introduce BlueStar C to truckers and fleets in attendance at the meeting. Access to and set up for BlueStar C will be available at MATS for the trucking audience.